WuXi PharmaTech, Pfizer Sign ADME Pact

WuXi PharmaTech has signed a new three-year, in vitro ADME collaboration agreement with Pfizer. The companies will establish ADME assays to provide in vitro screening services on compounds WuXi PharmaTech synthesizes for Pfizer. The evaluation of ADME properties is a key step in the drug discovery and development process. WuXi’s goal is to provide key information for the improvement of pharmacokinetic properties of Pfizer’s compounds.
   
The two companies have been involved in various collaborations, including synthetic chemistry, parallel medicinal chemistry (PMC), and ADME and bioanalytical services.
   
“This new agreement further strengthens our already productive relationship with Pfizer, one of our largest customers for many years, and it is the direct result of our research capability and firm commitment to quality and customer satisfaction,” said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech.
   
“A high quality and flexible Asia R&D partnership network is critical to Pfizer’s emerging market and Asia strategy. We want to build a strong relationship with leading CROs such as WuXi PharmaTech to tap into the scientific talents and R&D capabilities in Asia,” commented Dr. Steve Yang, vice president and head of Asia R&D at Pfizer.